1 We excluded 1 064 864 children born after 1998, 50 274 childr
2 I measurements, and overall survival data for analyses, and
we excluded 119 (26%) overweight patients, leaving a final co
3 We excluded 1413 (61%) women who were ineligible, declined to
4 We excluded 20 patients with insufficient or no systolic bloo
5 We excluded 3 items in order to avoid confounding findings: 2
6 We excluded 550 cases as patients were younger than 15 years,
7 From the 2423 (20%) underweight children,
we excluded 656 (27%) children who lived more than 30-min wal
8 We excluded all non-applicable trials, those not yet due to r
9 We excluded animal studies and trials in pediatric population
10 We excluded articles if the majority of patients were greater
11 We excluded babies for whom a PICC was not inserted from safe
12 We excluded case reports and case series, studies that measur
13 We excluded children who had a contraindication to an esophag
14 We excluded children younger than 1 year.
15 We excluded facilities with no recorded antenatal care attend
16 herapy and the control group (no anti-TNFalpha therapy) and
we excluded individuals with a cancer diagnosed before their
17 We excluded infants with life-threatening congenital malforma
18 We excluded mothers with diabetes, other medical conditions,
19 We excluded patients receiving end-of-life care.
20 We excluded patients who did not have a radiographic tumour a
21 We excluded patients who had end-stage kidney disease or AKI
22 We excluded patients who were already taking a beta-blocker o
23 We excluded patients with a radiological or clinical diagnosi
24 We excluded patients with contraindications to both deceased
25 We excluded patients with metastasis, node-positive disease,
26 We excluded patients younger than 18 years and those with adv
27 We excluded patients younger than 18 years, those with trauma
28 We excluded quality measures relating to outcomes because the
29 We excluded review articles and studies not available in Engl
30 We excluded review articles, case reports or case studies, an
31 We excluded studies concerning indwelling vascular catheters,
32 We excluded studies containing mixed cohorts of migrants and
33 We excluded studies evaluating cross-linking for nonectatic i
34 We excluded studies focusing on special populations, infants
35 We excluded studies in high-income countries, those involving
36 We excluded studies of patients with extrapulmonary tuberculo
37 We excluded studies of supplements, children, or individuals
38 We excluded studies performed in non-developed countries, and
39 We excluded studies whose population of interest was neonatal
40 We excluded studies with an active control agent (which might
41 We excluded subjects with concomitant heart defects and condi
42 Similar results were found when
we excluded the metropolitan area of Rome from the analysis.
43 ssibility of tyrosine phosphorylation-induced dimerization,
we excluded this possibility by using small-angle X-ray scatt
44 sent analysis, among patients enrolled in the ART (n=3102),
we excluded those who did not undergo surgery (n=25), had a h
45 We excluded those with rejection, graft coronary artery disea
46 We excluded those with systemic steroid use in the prior year
47 We excluded trials investigating therapeutic hypothermia in i
48 We excluded trials or conditions within trials that were not
49 We excluded trials that exclusively enrolled participants wit
50 We excluded women who had hysterectomy or oophorectomy and wo